Dominique PV de Kleijn,
Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute,
University Medical Center Utrecht, The Netherlands
Prof. Dr. Dominique PV de Kleijn is molecular biologist and chemist and professor of Exp. Vascular Surgery at UMC Utrecht and professor at the Netherlands Heart Institute. From 2012 to 2016, he was Research Professor of Surgery at NUS/NUHS and preclinical director of the Cardiovascular Research Institute (CVRI) Singapore. He was until 2016 professor of Cardiovascular Immunology and co-chair of Experimental Cardiology at UMC Utrecht. Since 1997 he is coordinating cardiovascular research from basic science, animal myocardial infarction and atherosclerotic studies (pig and sheep) towards clinical biobanking studies. His research interests are: The innate immune system in cardiovascular disease and atherosclerosis & Biomarkers predictive for primary & secondary events with a focus on plasma extracellular vesicles. He has more then 275 publications and a H-factor of 78.
|
|
Plasma Extracellular Vesicles for Cardiovascular DiseaseTuesday, 14 December 2021 at 12:00  Add to Calendar ▼2021-12-13 17:00:002021-12-13 18:00:00Europe/LondonExtracellular Vesicles: Liquid Biopsies and Biological Nanocarriers For TherapyExtracellular Vesicles (EVs): Technologies and Biological Investigations in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.comCardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. We are focussing on prognosis of secondary cardiovascular events after stroke and diagnosis of Ischemic Heart Disease. Ischemic heart disease (IHD) comprises 2 entities: Chronic Coronary Syndrome (CCS) and Acute Coronary Syndrome (ACS). Because CCS is associated with 6-8 times increased risk of adverse cadviovascular events like myocardial infarction and death, early recognition of CCS. Blood markers for CCS do not exist, resulting in that 80-90% of chest pain patients undergoing costly imaging do not have CCS. We use plasma extracellular vesicle protein content of vesicles from plasma subfractions as an accurate source for early diagnosis of CCS better then a clinical risk model. The same EV subfraction technology is used on plasma of stroke patients that after carotid atherectomy are at high risk of a second event (myocardial infarction, stroke or cardiovascular death). Protein as well as lipid content can identify patients at high risk for a secondary event better then a clinical risk prediction model.
|
